================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

-------------------
FORM 10-K/A
-----------
Amendment No. 1

[x] AMENDMENT TO ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31,
2000
or

[_] AMENDMENT TO TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934. For the transition period from
___________ to ___________

Commission file number: 0-30318

VENTIV HEALTH, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)

Delaware 52-2181734
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)

1114 Avenue of the Americas
8th Floor
New York, New York 10036
(212) 768-8000
- --------------------------------------------------------------------------------
(Address, Including Zip Code, and Telephone Number, Including Area Code, of
Registrant's Principal Executive Offices)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.001 per share

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [x] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statement
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]

The aggregate market value of the Registrant's Common Stock held by
non-affiliates was approximately $305,714,039 as of April 30, 2001.

As of April 30, 2001, there were 22,831,519 outstanding shares of the
Registrant's Common Stock, par value $.001 per share.

DOCUMENTS INCORPORATED BY REFERENCE:
None

================================================================================
NY2:\1040379\01\M@RF01!.DOC\79008.0003

EXPLANATORY NOTE

This Report on Form 10-K/A adds Part III to the Annual Report on Form
10-K of Ventiv Health, Inc. (the "Company") for the fiscal year ended December
31, 2000.

PART III

Item 10. Directors and Executive Officers of the Registrant.
- ------- --------------------------------------------------

As of May 1, 2000, the directors and executive officers of the Company,
their ages, the positions held by them and the periods during which they have
served in such positions are as follows:

Name Age Position with HomeFed Office Held Since
- ----- --- --------------------- -----------------

Daniel M. Snyder 36 Co-Chairperson of the Board 1999

Michele D. Snyder 38 Co-Chairperson of the Board 1999

Eran Broshy 42 Chief Executive Officer and Director 1999

Mortimer B. Zuckerman 63 Director 1999

Fred Drasner 58 Director 1999

A. Clayton Perfall 42 Director 1999

Donald Conklin 64 Director 1999

John R. Harris 52 Director 2000

The officers serve at the pleasure of the board of directors of the
Company.

The recent business experience of our executive officers and directors
is summarized as follows:

Daniel M. Snyder has served as the Co-Chairperson of the Board of the
Company since the Company's separation from Snyder Communications, Inc. in
September 1999. Mr. Snyder is the Owner and Chairman of the Washington Redskins
football team. Mr. Snyder was Chairman and a founder of Snyder Communications,
Inc. and served as Chief Executive Officer of Snyder and its predecessors from
1987 to September 2000.

Michele D. Snyder has served as the Co-Chairperson of the Board of the
Company since the Company's separation from Snyder Communications, Inc. in
September 1999. Ms. Snyder was a founder of Snyder Communications, Inc. and
served as President and Chief Operating Officer and a director of Snyder and its
predecessors from 1987 to September 2000. Ms. Snyder is Mr. Snyder's sister.

Eran Broshy has served as a director and the Chief Executive Officer of
the Company since the Company's separation from Snyder Communications, Inc. in
September 1999. Mr. Broshy served as the practice leader of the North American
healthcare consulting practice of the Boston Consulting Group from 1991 to 1998.
From 1998 to 1999, Mr. Broshy served as President and Chief Executive Officer of
Coelacanth Corporation, a privately-held biotechnology company.

Mortimer B. Zuckerman has been a director of the Company since
September 1999. Mr. Zuckerman has served as the Chairman of Boston Properties,
Inc., a national real estate development and management company, since 1970. He
also serves as Chairman of U.S. News & World Report, L.P. and Editor-in-Chief of
U.S. News & World Report, Chairman of Daily News, L.P. and Co-Publisher of the
New York Daily News, and Chairman of the Board of Directors of Applied Graphics
Technologies, Inc.

Fred Drasner has been a director of the Company since September 1999.
Mr. Drasner has been Chief Executive Officer of Daily News, L.P. and
Co-Publisher of the New York Daily News, since 1993. [Mr. Drasner also serves as
the co-Chairman of U.S. News & World Report, Chairman of Applied Graphics
Technologies, Inc., and Chairman and Chief Executive Officer of Applied Printing
Technologies.]

A. Clayton Perfall has been a director of the Company since the
Company's separation from Snyder Communications, Inc. in September 1999. He
currently serves as Chief Executive Officer of Convergence Holdings Corp. Prior
to taking this position in January 2001, Mr. Perfall served as the Chief
Financial Officer and a director of Snyder Communications, Inc. from 1996 to
September 2000. Prior to joining Snyder Communications, Inc., Mr. Perfall spent
fifteen years with Arthur Andersen LLP.

Donald Conklin has been a director of the Company since September 1999.
Prior to joining the Company's Board, Mr. Conklin worked for 37 years with
Schering-Plough Corporation. He was President of the worldwide pharmaceutical
operations for 10 years and Chairman of its Health Care Products division for
two years. Mr. Conklin is a member of the Board of Directors of Biotransplant,
Inc., Vertex Pharmaceuticals, Inc. and Alfa Cell, Inc.

John R. Harris has been a director of the Company since May 2000. Mr.
Harris is the Chairman and Chief Executive Officer of Ztango.com, a provider of
wireless Internet software and solutions for e-companies, wireless network
operators and corporations. Prior to joining Ztango.com in 1999, Mr. Harris
spent 25 years with Electronic Data Systems, during which he held a variety of
executive leadership positions encompassing sales, marketing, strategy and
operations, most recently served as Corporate Vice President, Marketing &
Strategy. Mr. Harris is a member of the Board of Directors of Applied Graphics
Corporation, World Commerce Online and Genuity, Inc.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's executive officers and directors, and persons who beneficially own
more than ten percent (10%) of a registered class of the Company's equity
securities, to file reports of ownership and changes in ownership with the
Securities and Exchange Commission and the Nasdaq National Market System. In
addition, under Section 16(a), trusts for which a reporting person is a trustee
and a beneficiary (or for which a member of his immediate family is a
beneficiary) may have a separate reporting obligation with regard to ownership
of the Common Stock and other equity securities of the Company. Such reporting
persons are required by rules of the Securities and Exchange Commission to
furnish the Company with copies of all Section 16(a) reports they file. Based
solely upon a review of the copies of such forms furnished to the Company and
written representations from the Company's executive officers, directors and
greater than ten percent (10%) beneficial stockholders, the Company believes
that during the year ended December 31, 2000, all persons subject to the
reporting requirements of Section 16(a) filed the required reports on a timely
basis, except that a Form 5 was not timely filed for each of Daniel M. Snyder
and Fred Drasner. Mr. Snyder and Mr. Drasner subsequently filed Form 5's to
report the transactions.

Item 11. Executive Compensation.
- ------- ----------------------

Summary Compensation Table

The following table sets forth information in respect of the
compensation of the Chief Executive Officer, and the other four most highly
compensated executive officers of the Company for fiscal years 2000, 1999 and
1998, where applicable.

Long-Term Compensation
Annual Compensation Awards
-------------------------------------- ----------------------------- ---------------
Restricted Securities All Other
---------
Other Annual Stock Underlying Compensation
------------
Name and Principal Position(s) Year Salary Bonus Compensation Award(s) Options/SARs (c) (d) (e)
- ------------------------------ ---- ------ ----- ------------ -------- ------------ -----------

Eran Broshy (1) 2000 $425,000 --- --- ---
Chief Executive Officer and 1999 $225,890 $75,000 $2,500,000 503,938
Director

Gregory S. Patrick (2) 2000 $250,000 --- --- ---
Chief Financial Officer 1999 $83,562 $40,000 $1,000,000 251,969

William C. Pollock (3) 2000 $289,000 $63,580 --- ---
President, US Sales 1999 $275,000 $158,125 $ 500,000 50,000
1998 $240,000 $155,000 --- 75,000

Leonard Vicciardo (4) 2000 $270,900 $66,000 --- ---
President, Health Products 1999 $258,400 $150,000 $ 200,000 75,000
Research 1998 $36,381 --- --- 90,000

Patrick Fourteau (5) 2000 $257,308 $80,000 $ 300,000 50,000
President, Ventiv Europe

(1) Mr. Broshy joined Ventiv Health, Inc. in June 1999. Of the 314,961
shares awarded to Mr. Broshy pursuant to his restricted stock award,
125,984 shares, representing forty percent of Mr. Broshy's restricted
shares of Common Stock, having a market value of $1,582,674 as of
December 31, 2000, had vested as of September 27, 2000. The balance of
188,977 shares representing the remaining sixty percent of such
restricted shares will vest in equal installments over the next three
years.

(2) Mr. Patrick joined the Company in September 1999. Of the 125,984
shares awarded to Mr. Patrick pursuant to his restricted stock award,
69,292 shares representing fifty-five percent of Mr. Patrick's
restricted shares of Common Stock, having a market value of $870,481 as
of December 31, 2000, had vested as of September 27, 2000. Subsequent
to December 31, 2000, as announced in a press release on February 15,
2001, Mr. Patrick resigned as the Company's Chief Financial Officer. As
a result, the unvested portion of his restricted shares (56,692 shares)
were cancelled.

(3) Of the 62,992 shares awarded to Mr. Pollock pursuant to his
restricted stock award, 34,646 shares representing fifty-five percent
of Mr. Pollock's restricted shares of Common Stock, having a market
value of $435,240 as of December 31, 2000, had vested as of September
27, 2000. The balance of 28,346 shares representing the remaining
forty-five percent of such restricted shares will vest in equal
installments over the next three years. The 1998 issuance of stock
options of 75,000 for Mr. Pollock consisted of options to purchase
shares of Snyder Communications, Inc. common stock, which expired as a
result of the separation of the Company from Snyder Communications,
Inc.

(4) Mr. Vicciardo joined Health Products Research, Inc. in November
1998. Of the 25,197 shares awarded to Mr. Vicciardo pursuant to his
restricted stock award, 13,859 shares representing fifty-five percent
of Mr. Vicciardo's restricted shares of Common Stock, having a market
value of $174,104 as of December 31, 2000, had vested as of September
27, 2000. The balance of 11,338 shares representing the remaining
forty-five percent of such restricted shares will vest in equal
installments over the next three years. The 1998 issuance of stock
options of 90,000 for Mr. Vicciardo consisted of options to purchase
shares of Snyder Communications, Inc. common stock, which expired as a
result of the separation of the Company from Snyder Communications,
Inc.

(5) Mr. Fourteau joined Ventiv Health in January 2000. Had Mr. Fourteau
been employed by Ventiv Health, Inc. since the beginning of 2000, he
would have received an annual salary of $270,000. Mr. Fourteau was
awarded 29,448 shares of restricted stock. At December 31, 2000, none
of his restricted shares had vested. The restricted shares will vest in
equal installments over the next four years.

(6) Options to purchase Common Stock vest at a rate of 25% per year on
each anniversary of the grant date, provided the employee is still
employed by the Company on the applicable vesting date.

Option Grants in Fiscal 2000

The following table sets forth information with respect to option grants during
fiscal 2000 to the individuals named in the Summary Compensation Table pursuant
to the 1999 Stock Incentive Plan. No stock options were exercised in 2000 by
individuals listed in the chart below.

Annual Compensation
-------------------
Potential Realizable Value at
% of Total Assumed Annual Rates of Stock
Securities options Price Appreciation for
Underlying Granted to Exercise Option Term
Options Granted Employees in Price Expiration -----------
Name (# of shares) 2000 ($/Sh) Date 5%($) 10%($)
- ---- ------------- ---- ------ ---- ----- ------

Eran Broshy --- --- --- --- --- ---
Gregory S Patrick --- --- --- --- --- ---
William C. Pollock --- --- --- --- --- ---
Leonard Vicciardo --- --- --- --- --- ---
Patrick Fourteau 50,000 8.2% 10.1875 1/24/10 $829,718 $1,321,188

Compensation of Directors

John R. Harris received options to purchase 50,000 shares of Common
Stock. Mr. Harris's option grant vests at a rate of 25% per year on the
anniversary of the grant date, provided that he is still a member of the Board
of Directors of the Company on the applicable vesting date. In addition, this
option grant fully vests upon a change of control. In addition, Donald Conklin
and John Harris receive compensation of $25,000 per annum plus the sum of $1,000
per meeting attended.

Executive Employment Contracts

The Company has entered into employment agreements with each of the
named officers below and on such terms and conditions as are described.

Eran Broshy. On June 14, 1999, Snyder Communications, Inc. retained the
services of Mr. Broshy as President of Snyder Communications, Inc.'s healthcare
group. Under the terms of Mr. Broshy's employment agreement, which was assumed
by the Company in connection with the spin-off from Snyder Communications, Inc.,
he initially received an annual base salary of $425,000. He is also eligible for
an annual bonus award based on certain performance measures, which may not
exceed $125,000.

Under his employment agreement, the Company granted to Mr. Broshy
503,938 non-qualified options to purchase Common Stock at an exercise price
equal to $7.9375, the closing price of Company Common Stock on the date of the
spin-off. Mr. Broshy's options vest at the rate of 25% per year on each
anniversary of the grant date, provided he is still employed by the Company on
the applicable vesting date. Mr. Broshy's employment agreement also provides for
a grant of an aggregate of $2,500,000 in restricted Common Stock, 20% of which
vested on the distribution date and the remaining 80% vesting in equal
increments over the next four years, provided he is still employed by the
Company on the applicable vesting date. The restricted stock grant provided for
in his employment agreement will prohibit Mr. Broshy from transferring any of
his Common Stock for a period of four years after the distribution date. The
agreement provides that upon a "change in control" of the Company, the vesting
of both the stock options and restricted stock will accelerate so that Mr.
Broshy's options and restricted stock are fully vested. For purposes of his
employment agreement, "change in control" means any sale, transfer or other
disposition of all or substantially all of the assets of the Company or the
consummation of a merger or consolidation of the Company which results in the
Company's stockholders immediately prior to such transaction owning, in the
aggregate, less than a majority of the surviving entity. Furthermore, Mr.
Broshy's employment agreement provides that he may borrow up to $500,000 from
the Company exclusively for the purchase of Common Stock.

Gregory S. Patrick. In September 1999, the Company retained the
services of Mr. Patrick as Chief Financial Officer. Under the terms of Mr.
Patrick's employment agreement, he initially received an annual base salary of
$250,000. He is also eligible for an annual bonus award based on certain
performance measures, which may not exceed $100,000. Under his employment
agreement, the Company granted to Mr. Patrick non-qualified options to purchase
an aggregate of 251,969 shares of Common Stock at an exercise price equal to
$7.9375, the closing price of Common Stock on the distribution date. Mr.
Patrick's options vest at the rate of 25% per year on each anniversary of the
grant date, provided he is still employed by the Company on the applicable
vesting date. Mr. Patrick's employment agreement also provided for a grant of an
aggregate of $1,000,000 shares in restricted Common Stock, 40% of which vested
on the distribution date, with the remaining 60% vesting in equal increments
over the next four years, provided he is still employed by the Company on the
applicable vesting date. The restricted stock grant provided for in his
employment agreement will prohibit Mr. Patrick from transferring any of his
Common Stock for a period of four years after the distribution date.
Furthermore, Mr. Patrick's employment agreement provides that he may borrow from
the Company an amount necessary to pay any federal and state income taxes
resulting from the restricted stock grant. Subsequent to December 31, 2000, as
announced in a press release on February 15, 2001, Mr. Patrick resigned as the
Company's Chief Financial Officer. As a result, the unvested portion of his
restricted shares (56,692 shares) and unvested stock options (188,976 shares)
were cancelled.

William C. Pollock. The Company entered into a new employment agreement
with Mr. Pollock dated as of January 1, 2001. Mr. Pollock's initial base salary
under his employment agreement is $300,000. He is also eligible for an annual
bonus award, based on certain performance measures, of zero to sixty percent of
his then current base salary. Under his employment agreement, the Company
granted to Mr. Pollock non-qualified options to purchase an aggregate of 25,000
shares of Common Stock at an exercise price equal to the closing price of a
share of Common Stock on January 29, 2001, the grant date. Under this employment
agreement and previous agreements, the Company has granted Mr. Pollock
non-qualified options to purchase an aggregate of 75,000 shares of Common Stock.
Mr. Pollock's options vest at the rate of 25% per year on each anniversary of
the grant date, provided he is still employed by the Company on the applicable
vesting date. In the event of Mr. Pollock's termination of employment without
cause (as defined in his employment agreement), Mr. Pollock is entitled to a
severance payment equal to one half of his annual base salary. In the event of a

change of control (as defined in his employment agreement) of the Company, Mr.
Pollock is entitled to a payment equal to his annual base salary, paid in two
equal installments, subject to his continued employment and his not being
terminated for any reason other than without cause.

Leonard Vicciardo. Mr. Vicciardo's previous employment agreement with
Health Products Research, Inc., a subsidiary of the Company, dated October 26,
1998, has expired. The Company expects to enter into a new employment agreement
with Leonard Vicciardo effective as of January 29, 2001. The terms of Mr.
Vicciardo's new employment agreement are expected to include an annual base
salary of $273,000, an annual bonus award based on certain performance measures,
up to his then current base salary, the grant to Mr. Vicciardo of non-qualified
options to purchase an aggregate of 12,000 shares of Common Stock at an exercise
price equal to the closing price of a share of Common Stock on January 29, 2001,
the grant date. Under this employment agreement and previous agreements, the
Company has granted Mr. Vicciardo non-qualified options to purchase an aggregate
of 87,000 shares of Common Stock. Mr. Vicciardo's options will vest at the rate
of 25% per year on each anniversary of the grant date, provided he is still
employed by the Company on the applicable vesting date. Under the terms of the
new employment agreement, in the event of Mr. Vicciardo's termination of
employment without cause (as defined in his employment agreement), Mr. Vicciardo
will be entitled to a severance payment equal to the lesser of the continuation
of his base salary for a period of 26 weeks from the termination date or
continuation of his base salary for a period from the termination date until he
obtains new employment. In addition, in the event of a change of control (as
defined in his employment agreement) of the Company, Mr. Vicciardo will be
entitled to a payment equal to his annual base salary, paid in two equal
installments, subject to his continued employment and his not being terminated
for any reason other than without cause.

Patrick Fourteau. Ventiv Health, Inc. entered into an employment
agreement with Patrick Fourteau on January 24, 2000. Mr. Fourteau's initial base
salary under his employment agreement is $270,000. The Company granted him
options to purchase 50,000 shares of common stock at an exercise price of
$10.1875 per share, vesting over a four-year period. In the event of Mr.
Fourteau's termination without cause, restrictions on 50% of his vested
restricted shares lapse, and he is entitled to a severance payments of
one-quarter of his annual salary, plus salary until he gains new employment up
to another one-quarter of his annual salary. In the event of a change of control
of the Company, Mr. Fourteau is entitled to a payment equal to his annual base
salary, paid in two installments, subject to his continued employment and his
not being terminated for any reason other than without cause..

Each of the employment agreements described above contains a
non-competition commitment during the term of employment and for a period of 12
months after termination of employment. Additionally, each employment agreement
contains a non-solicitation provision and provides for assignment by the
employee to his employer of any work products developed by him during the term
of his employment.

Compensation Committee Interlocks

During 2000, the Board of Directors was responsible for the
establishment of the general compensation policies of the Company. Throughout
2000, Eran Broshy, the Chief Executive Officer of the Company, also served as a
director of the Company. Mr. Broshy absented himself from all discussions
relating to, and abstained from voting on, resolutions concerning his own
compensation.

Item 12. Security Ownership of Certain Beneficial Owners and Management.
- --------------------------------------------------------------------------

The following table sets forth certain information, to the knowledge of
the Company, as of April 23, 2001 (except as otherwise noted), with respect to
the beneficial ownership of the Common Stock by (i) each person known to the
Company to be the beneficial owner of more than 5% of the outstanding Common
Stock, (ii) each director and nominee for director, (iii) each of the executive
officers of the Company named in the Summary Compensation Table under "Executive
Compensation," and (iv) all directors and executive officers of the Company as a
group.

Number of Shares
and Nature of Percent
Name of Beneficial Owner Beneficial Ownership of Class (1)
- ------------------------ -------------------- ------------

Daniel M. Snyder (2) .............................................. 2,797,914 12.3%
Michele D. Snyder (3) ............................................. 1,151,490 5.0%
Mortimer B. Zuckerman (4).......................................... 1,646,016 7.2%
Fred Drasner (5)................................................... 755,204 3.3%
A. Clayton Perfall (6)............................................. 25,000 *
Don Conklin (7) ................................................... 12,500 *
John R. Harris (8) 12,500 *
Eran Broshy (9).................................................... 296,969 1.3%
Gregory Patrick (10)............................................... 132,284 *
Leonard Vicciardo (11)............................................. 51,358 *
William C. Pollock (12)............................................ 114,375 *
Patrick Fourteau (13) 21,862 *
The TCW Group (14)................................................. 3,297,404 14.4%
Capital Research and Management Co. (15)........................... 1,983,330 8.7%
RS Investment Management Co. LLC (16) 1,489,000 6.5%
All directors and executive officers as a group (12 persons) (17).. 7,017,472 30.7%
*Denotes less than 1%.

(1) Based upon 22,831,519 shares of Common Stock outstanding as of April 30,
2001.

(2) Includes 37,500 shares of common stock issuable upon exercise of options.
The address for Daniel M. Snyder is 21300 Redskin Park Drive, Ashburn,
Virginia 20147.

(3) Includes 37,500 shares of common stock issuable upon exercise of options.
Includes 92,816 shares subject to a forward purchase contract with
unaffiliated third party. The contract obligates the contracting party to
deliver shares or cash on a pre-arranged settlement date. To the extent
that the value of the common stock appreciates between the date of the
contract and the settlement date, the number of shares or amount of cash
that must be delivered on the settlement date is reduced pursuant to a
formula contained in the contract. Prior to the settlement date, Ms. Snyder
or her affiliate described below retains voting and dividend rights with
respect to the shares that are the subject of the contract. Pursuant to the
contract, the settlement date is the third trading day following July 30,
2001. The address for Michele D. Snyder is c/o Ventiv Health, Inc., 1114
Avenue of the Americas, New York, New York, 10036.

(4) Consists of shares of common stock held by USN College Marketing, L.P.
("College Marketing") (a limited partnership in which USN College
Marketing, Inc. ("USN Inc.") is the general partner and Fred Drasner is the
sole limited partner) and attributable to USN Inc.'s general partnership
interest in College Marketing. USN Inc. is owned one third by Mortimer B.
Zuckerman and two thirds by the MBZ Trust of 1996, for which an outside
person acts as the Trustee. Mr. Zuckerman is the sole director of USN Inc.
Includes 211,537 shares of common stock owned by USN, Inc. subject to a
forward purchase contract with an unaffiliated third party. The contract
obligates the contracting party to deliver shares or cash on the third
trading day following July 30, 2001. To the extent that the value of the

common stock appreciates between the date of the contract and its
settlement date, the number of shares or amount of cash that must be
delivered on the settlement date is reduced pursuant to a formula contained
in the contract. Prior to the settlement date, College Marketing retains
voting and dividend rights with respect to the shares that are the subject
of the contract. Does not include 355,104 shares held by College Marketing
that are beneficially owned by Mr. Drasner. See Note 5. Also includes
25,000 shares of common stock issuable upon exercise of options. Mr.
Zuckerman's address is 599 Lexington Avenue, Suite 1300, New York, New York
10022. The address of MBZ Trust of 1996 is c/o Boston Properties, 8
Arlington Street, Boston, Massachusetts 02116.

(5) Consists of (i) 108,434 shares owned by Mr. Drasner in his individual
capacity and over which he exercises sole voting and investment discretion,
(ii) 355,104 shares beneficially owned by Mr. Drasner as limited partner in
College Marketing and (iii) 266,666 shares beneficially owned by Mr.
Drasner as a result of his ownership of F.D. Sutton, LLC ("Sutton") a
limited liability company of which Mr. Drasner is the sole member. Also
includes 25,000 shares of common stock issuable upon exercise of options.

(6) Includes 25,000 shares of common stock issuable upon exercise of options.

(7) Consists of options to purchase 12,500 shares of Ventiv common stock.

(8) Consists of options to purchase 12,500 shares of Ventiv common stock.

(9) Includes 125,985 shares of common stock issuable upon exercise of options
and 125,984 shares of unvested, restricted stock.

(10) Includes 62,993 shares of common stock issuable upon exercise of options
and 69,291 shares of vested, restricted stock.

(11) Includes 37,500 shares of common stock issuable upon exercise of options
and 13,858 shares of vested, restricted stock.

(12) Includes 37,500 shares of common stock issuable upon exercise of options
and 34,646 shares of vested, restricted stock.

(13) Includes 12,500 shares of common stock issuable upon exercise of options
and 7,362 shares of vested, restricted stock.

(14) Ownership is as reported in Schedule 13G of the TCW Group, Inc. ("TCW") and
is as of February 14, 2001. TCW's address is 865 South Figueroa Street, Los
Angeles, California, 90017.

(15) Ownership is as reported in Schedule 13G of Capital Research and Management
Co. ("Capital") and is as of February 12, 2001. Capital's address is 333
South Hope Street, 55th Floor, Los Angeles, California 90071.

(16) Ownership is as reported in Schedule 13G of RS Investment Management Co.
LLC ("RSIM") and is as of February 15, 2001. No known address.

(17) Includes 451,478 shares of common stock issuable upon exercise of options
and 251,141 shares of vested, restricted stock.

Item 13. Certain Relationships and Related Transactions.
- --------------------------------------------------------

None

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf by the
undersigned, thereunto duly authorized.

VENTIV HEALTH, INC.
Registrant

By: /s/ Joseph S. Durko
-----------------------------------
Joseph S. Durko
Vice President, Controller and Secretary
Dated: May 1, 2001